参考文献/References:
[1] Kucukalc 6-Selimovc E, Alagic J,Valjevac A, et al. The value of serum thyreoglobulin levels and whole body(l-131) scintigraphy in the follow-up of the thyroid cancer patients after thyroidectomy.Coll Antropol, 2012,36 suppl 2:S67-71.
[2] Lind P. 131I whole body scintigraphy in thyroid cancer patients. Q J NucI Med, 1999, 43(3):188-194.
[3] Samuel AM, Rajashekharrao B, Shah DH. Pulmonary metastases in children and adolescents with well-differentiated thyroid cancer. J Nucl Med, 1998,39(9):1531-1536.
[4] Zanotti-Fregonara P, Keller I,Rubello D, et al. Thyrotropin varia-tions may explain some positive radioiodine therapy scans in patients with negative diagnostic scans. J Endocrinol Invest, 2009,32(3):267-271.
[5] Alagic-Smailbegovic J, Kucukalic-Selimovic E,Setic I,et al. Impor-tance of measurement of thyroglobulin and anti-thyroglobulin anti-bodies in differentiated thyroid cancer. Coll Antropol, 2012, 36suppl 2:S33-38.
[6] Fatourechi V, Hay ID. Treating the patient with differentiated thy-roid cancer with thyroglobulin-positive iodine-131 diagnostic scan-negative metastases:including comments on the role of serum thyroglobulin monitoring in tumor surveillance. Semin Nucl Med,2000,30(2):107-114.
[7] Dong MJ, Liu ZF, Zhao K, et al. Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan:a meta-analysis. Nucl Med Commum, 2009, 30(8):639-650.
[8] Kunawudhi A, Pak-art R, Keelawat S, et al. Detection of subcen-timeter metastatic cervical lymph node by 18F-FDG PET/CT in patients with well-differentiatedthyroid carcinoma and high serumthyroglobulin but negative 131I whole-body scan. Clin Nucl Med,2012, 37(6):561-567.
相似文献/References:
[1]李盼丽,宋少莉.碘难治性分化型甲状腺癌靶向药物治疗进展[J].国际放射医学核医学杂志,2016,40(3):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
Li Panli,Song Shaoli.Radioactive iodine refractory differentiated thyroid cancer targeted therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
[2]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[3]陈立,陈跃.分化型甲状腺癌骨转移诊断及疗效评价的核素显像研究进展[J].国际放射医学核医学杂志,2016,40(6):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
Chen Li,Chen Yue.Diagnosis and evaluation of curative effect progress of radionuclide imaging methods in differentiated thyroid cancer of bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
[4]赵腾,梁军,林岩松.131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义[J].国际放射医学核医学杂志,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
Zhao Teng,Liang Jun,Lin Yansong.The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
[5]刘斌,潘明志.BRAF基因突变对甲状腺乳头状癌诊治价值的研究进展[J].国际放射医学核医学杂志,2015,39(2):154.[doi:10.3760/cma.j.issn.1673-4114.2015.02.011]
Liu Bin,Pan Mingzhi.Advances in value of BRAF gene mutation on the diagnosis and treatment of papillary thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):154.[doi:10.3760/cma.j.issn.1673-4114.2015.02.011]
[6]刘鹏杰,唐铭,邓智勇,等.131I治疗儿童分化型甲状腺癌期间出现低钙血症伴癫痫发作一例[J].国际放射医学核医学杂志,2015,39(4):352.[doi:10.3760/cma.j.issn.1673-4114.2015.04.017]
[7]寇莹,刘建中,郝新忠,等.甲状腺癌131I治疗后全身扫描盆腔浓聚131I的临床分析[J].国际放射医学核医学杂志,2014,38(1):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
Kou Ying,Liu Jianzhong,Hao Xinzhong,et al.Analysis of pelvic 131I uptake after 131I whole body scan in patients with thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(5):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
[8]李敬彦,蒋宁一.分化型甲状腺癌术后131I清甲治疗方法的相关问题[J].国际放射医学核医学杂志,2014,38(1):42.[doi:10.3760/cma.j.issn 1673-4114.2014.01.009]
Li Jingyan,Jiang Ningyi.Issues related to radioactive iodine ablation in patients with differentiated thyroid carcinoma under-going thyroid surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(5):42.[doi:10.3760/cma.j.issn 1673-4114.2014.01.009]
[9]成钊汀,谭建.分化型甲状腺癌术后患者131I治疗的辐射剂量与防护[J].国际放射医学核医学杂志,2014,38(2):110.[doi:10.3760/cma.j.issn.1673-4114.2014.02.010]
Cheng Zhaoting,Tan Jian.Radiation dose and protection of differentiated thyroid carcinoma postoperative patients with 131I treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(5):110.[doi:10.3760/cma.j.issn.1673-4114.2014.02.010]
[10]李莉,晋建华,陆克义,等.131I去除分化型甲状腺癌术后残留甲状腺组织疗效的meta分析[J].国际放射医学核医学杂志,2014,38(3):152.[doi:10.3760/cma.j.issn.1673-4114.2014.03.003]
Li Li,Jin Jianhua,Lu Keyi,et al.A meta-analysis of efficacy of iodine-131 for post-thyroidectomy ablation of remnants in patients with differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(5):152.[doi:10.3760/cma.j.issn.1673-4114.2014.03.003]
[11]惠金子,赵德善.Tg、TgAb及TSH在分化型甲状腺癌术前的预测分析[J].国际放射医学核医学杂志,2015,39(2):110.[doi:10.3760/cma.j.issn.1673-4114.2015.02.002]
Hui Jinzi,Zhao Deshan.The prediction of risk of differentiated thyroid carcinoma with preoperative serum thyroid stimulating hormone, thyrogiobulin and antithyroglobulin antibody[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):110.[doi:10.3760/cma.j.issn.1673-4114.2015.02.002]
[12]胡斌,王锦锋,毛秋粉.18F-FDG PET/CT显像在Tg阳性131I全身显像阴性的分化型甲状腺癌患者中的应用价值[J].国际放射医学核医学杂志,2015,39(3):242.[doi:10.3760/cma.j.issn.1673-4114.2015.03.012]
Hu Bin,Wang Jinfeng,Mao Qiufen.The application value of 18F-FDG PET/CT in patients with differentiated thyroid cancer of high thyroglobulin level and negative 131I whole body scan[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):242.[doi:10.3760/cma.j.issn.1673-4114.2015.03.012]
[13]龙再颖,汤春静,于立明,等.甲状腺乳头状癌术后刺激状态Tg与颈部淋巴结转移关系的研究[J].国际放射医学核医学杂志,2013,37(1):27.[doi:10.3760/cma.j.issn.1673-4114.2013.01.008]
LONG Zai-ying,TANG Chun-jing,YU Li-ming,et al.The correlation between the stimulated thyroglobulin level after surgery in papillary thyroid carcinoma and cervical lymph node metastasis[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(5):27.[doi:10.3760/cma.j.issn.1673-4114.2013.01.008]
[14]邱忠领,罗全勇.甲状腺球蛋白与分化型甲状腺癌[J].国际放射医学核医学杂志,2009,33(2):89.[doi:10.3760/cma.j.issn.1673-4114.2009.02.008]
QIU Zhong-ling,LUO Quan-yong.Thyroglobulin and differentiated thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(5):89.[doi:10.3760/cma.j.issn.1673-4114.2009.02.008]
[15]林军,缪蔚冰,吴立坚,等.131I治疗分化型甲状腺癌转移灶中甲状腺球蛋白测定和131I-全身显像的意义[J].国际放射医学核医学杂志,2006,30(3):161.
LIN Jun,MIAO Wei-bing,WU Li-jian,et al.The value of thyroglobulin measured and 131I-whole body scan on the differentiated thyroid carcinoma with 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(5):161.